Presenilin is the catalytic component of g-secretase, a complex aspartyl protease and a founding member of intramembrane-cleaving proteases. g-Secretase is involved in the pathogenesis of Alzheimer's disease and a top target for therapeutic intervention. However, the protease complex processes a variety of transmembrane substrates, including the Notch receptor, raising concerns about toxicity. Nevertheless, g-secretase inhibitors and modulators have been identified that allow Notch processing and signaling to continue, and promising compounds are entering clinical trials. Molecular and biochemical studies offer a model for how this protease hydrolyzes transmembrane domains in the confines of the lipid bilayer. Progress has also been made toward structure elucidation of presenilin and the g-secretase complex by electron microscopy as well as by studying cysteine-mutant presenilins. The signal peptide peptidase (SPP) family of proteases are distantly related to presenilins. However, the SPPs work as single polypeptides without the need for cofactors and otherwise appear to be simple model systems for presenilin in the g-secretase complex. SPP biology, structure, and inhibition will also be discussed.
Introduction
Intramembrane-cleaving proteases (I-CLiPs) are multi-pass membrane proteins that process the transmembrane regions of their substrates and have their active sites lying within the confines of the lipid bilayer (Wolfe, 2009) . So far, I-CLiPs have been identified that are metalloproteases (the S2P family), serine proteases (the rhomboid family) and aspartyl proteases wthe presenilin and signal peptide peptidase (SPP) familiesx. These proteases are found in all forms of life and play a variety of roles in biology and disease. Presenilin is part of a large protease complex called g-secretase, involved in Alzheimer's disease, cell signaling, and membrane protein degradation (Selkoe and Wolfe, 2007) . Members of the SPP family require no additional protein factors and are otherwise simpler enzymes compared with the distantly related presenilins (Fluhrer et al., 2009) . In this review, we will discuss the role of presenilin and the g-secretase complex in Alzheimer's disease and in basic cell biology, how this enzyme hydrolyzes transmembrane substrates, the prospects of developing Alzheimer therapeutics that target g-secretase, progress toward elucidating the structure of g-secretase, and how the SPP family could provide insight into presenilin structure and function in the g-secretase complex.
Presenilin in Alzheimer's disease
A key step in the pathogenesis of Alzheimer's disease is proteolysis of the amyloid b-protein precursor (APP) that results in the formation of the amyloid b-protein (Ab) (Figure 1A) , the principle protein component of the characteristic cerebral plaques of the disease (Hardy and Selkoe, 2002; Tanzi and Bertram, 2005) . The N-terminus of Ab is produced from APP first by the action of b-secretase, a membrane-tethered pepsin-like aspartyl protease (Cole and Vassar, 2008) . This proteolysis leads to membrane shedding of the large luminal/extracellular APP domain. The 99-residue membrane-bound remnant is then cleaved by g-secretase in the middle of its transmembrane region at the g-site, releasing Ab, and also near the inner leaflet at the´site to release the APP intracellular domain (AICD) (Weidemann et al., 2002; see APP in Figure 1A ). Rare mutations in the APP gene, found in and around the small Ab region, cause familial early-onset Alzheimer's disease, and these mutations alter the production of Ab or its aggregation properties, important evidence for the amyloid hypothesis of Alzheimer pathogenesis (Hardy and Selkoe, 2002; Tanzi and Bertram, 2005) .
Crucial clues to the identity of g-secretase included: (1) Genes encoding the multi-pass membrane proteins presenilin-1 and presenilin-2 are, like APP, associated with familial, early-onset Alzheimer's disease (Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995) . The diseasecausing missense mutations were found to alter how g-secretase cuts APP, leading to increased proportions of longer, more aggregation-prone forms of Ab (Duff et al., 1996; Lemere et al., 1996; Scheuner et al., 1996; Citron et al., 1997) . (2) Knockout of presenilin genes eliminates g-secretase cleavage of APP (De Strooper et al., 1998; Herreman et al., 2000; Zhang et al., 2000) . (3) Peptidomimetics that inhibit g-secretase contain moieties typically found in aspartyl protease inhibitors (Wolfe et al., 1999b; Shearman et al., 2000) . These findings led to the identification of two conserved transmembrane aspartates in the multi-pass presenilins that are crucial for g-secretase cleavage of APP ( Figure  1A ), evidence that presenilins are aspartyl proteases (Steiner et al., 1999; Wolfe et al., 1999c) .
Presenilin is endoproteolytically cleaved into two polypeptides, an N-terminal fragment (NTF) and a C-terminal fragment (CTF) (see Figure 1A ; Podlisny et al., 1997; Ratovitski et al., 1997) , the formation of which is regulated , metabolically stable (Podlisny et al., 1997; Ratovitski et al., 1997; Capell et al., 1998; Yu et al., 1998; Zhang et al., 1998) , and part of a high-molecular weight complex (Capell et al., 1998; Yu et al., 1998) , suggesting that the NTF-CTF heterodimer is the biologically active form (Laudon et al., 2004) . NTF and CTF each contribute one of the essential and conserved aspartates, and transition-state analog inhibitors of g-secretase, compounds designed to interact with the active site of the protease, bind directly to presenilin NTF and CTF (Esler et al., 2000; Li et al., 2000b) . Although this evidence suggests that presenilin is an aspartyl protease, presenilins do not work alone and are part of a larger multi-protein complex that constitutes g-secretase (see below).
Notch and other g-secretase substrates
Presenilins are also required for Notch signaling (Levitan and Greenwald, 1995) , a pathway essential for cell differentiation during development and beyond (Selkoe and Kopan, 2003) . After Notch is synthesized in the ER, the receptor is cleaved in its extracellular domain during its passage through the secretory pathway, and the two pieces so generated remain associated (Logeat et al., 1998) . Upon interaction with a cognate ligand, Notch becomes susceptible to a second extracellular proteolysis, by a membrane-tethered metalloprotease, ADAM17, near the membrane (Brou et al., 2000; Mumm et al., 2000; see Figure 1A ). The membrane-associated remnant is then cleaved within its transmembrane domain by a presenilin-dependent g-secretase-like protease (De Strooper et al., 1999) , releasing the Notch intracellular domain (NICD). NICD translocates to the nucleus and activates transcription after associating with the nuclear partner CSL (Schroeter et al., 1998) .
Since the discovery that Notch is cleaved by g-secretase, many other substrates have been identified, including Erb-B4, E-and N-cadherins, CD44, the low density lipoprotein receptor, Nectin-1, and the Notch ligands Delta and Jagged (De Strooper, 2003; Beel and Sanders, 2008 ; see Figure 1B ). Transition-state analog inhibitors such as the peptidomimetic 1 include hydroxyl-containing moieties that interact with the catalytic aspartates of aspartyl proteases. Helical peptide inhibitors include a-aminoisobutyric acid (Aib)-containing substrate mimics such as 2 (*denotes that the threonine residue contains an O-benzyl group). These helical peptides mimic the APP transmembrane domain and interact with the substrate docking site on the protease. The potent benzodiazepine inhibitor 3 (LY-450,139) is in late-stage clinical trials for the treatment of Alzheimer's disease. NSAID-like modulator 4 (R-Flurbiprofen or tarenflurbil), which recently failed in late-stage clinical trials for Alzheimer's disease, shifts where g-secretase cuts APP, reducing the aggregation-prone Ab42 and elevating more soluble Ab38. Naphthyl ketone 5 inhibits total Ab production without interfering with the ability of g-secretase to cleave Notch receptor substrates.
Although cellular function can be ascribed in some cases, the ability of g-secretase to cleave so many different substrates and its apparently poor sequence specificity raise the question of whether a major role of this enzyme is to serve as a general degrading protease for membrane-bound protein remnants (Kopan and Ilagan, 2004) .
The g-secretase complex
The highly conserved role of g-secretase in Notch signaling and its importance in development led to genetic screens in Caenorhabditis elegans that identified three other integral membrane proteins in addition to presenilin that modify Notch signaling: nicastrin, APH-1, and Pen-2 (Goutte et al., 2000 (Goutte et al., , 2002 Francis et al., 2002) . Nicastrin was independently isolated biochemically as a presenilin-associated protein and found to be essential for g-secretase processing of both APP and Notch (Yu et al., 2000) . All four proteins (presenilin, nicastrin, Aph-1, and Pen-2) associate with one another (Kimberly et al., 2003; Takasugi et al., 2003) and with an immobilized g-secretase inhibitor (Esler et al., 2002; Kimberly et al., 2003) . Moreover, their coexpression increased g-secretase activity in both Drosophila and mammalian cells (Kimberly et al., 2003; Takasugi et al., 2003) and reconstituted activity in yeast (Edbauer et al., 2003) . This quartet of proteins ( Figure 1C ) is necessary and sufficient for g-secretase activity, formally demonstrated through purification of the protease complex to virtual homogeneity (Fraering et al., 2004) .
The stoichiometry of these four proteins in the g-secretase complex has been a matter of some controversy, with discrepancies in the reported size of the complex and in the number of presenilin molecules per complex. Sizes of 100-150 kDa to 2 MDa have been reported (Capell et al., 1998; Yu et al., 1998; Li et al., 2000a; Edbauer et al., 2002; Kimberly et al., 2003; Evin et al., 2005) , and several studies suggested that two presenilins reside at the catalytic core of the protease complex (Schroeter et al., 2003; Cervantes et al., 2004; Clarke et al., 2006) . However, rigorous biochemical and biophysical experiments have shown that isolated, active complexes contain only one of each component and, consistent with this stoichiometry, that the size of the purified enzyme is approximately 230 kDa, as determined by scanning electron microscopy (Osenkowski et al., 2009 ).
Inhibitors and modulators
Designed inhibitors have proven to be useful tools in understanding the mechanism of g-secretase and substrate recognition. As indicated above, transition-state analog inhibitors (e.g., compound 1, Figure 2 ) provided the first clear clue that the enzyme is an aspartyl protease, leading to the identification of two conserved and essential aspartates in presenilin. Moreover, affinity labeling with transition-state analog inhibitors showed binding at the interface between the presenilin NTF and CTF subunits, consistent with the active site residing at this interface, with each presenilin subunit contributing one of the essential aspartates.
Among the more intriguing questions about the entire emerging family of I-CLiPs is how they handle substrates and cleave within their TMDs, and again, small-molecule inhibitors have helped answer this question. Integral membrane substrates should require docking on the outer surface of the protease, with lateral gating to bring the substrate into the internal active site (Wolfe et al., 1999a) . Initial evidence for such a mechanism came from isolation of the g-secretase complex with an immobilized transition-state analog inhibitor: g-secretase complex members copurified with an endogenous APP substrate of the enzyme (Esler et al., 2002) . Because the protease active site was blocked by the immobilized transition-state analog inhibitor, this result suggested the existence of a separate substrate binding site.
Designed peptides based on the transmembrane domain of APP and constrained in a helical conformation (e.g., compound 2, Figure 2 ) can potently inhibit g-secretase, apparently by interacting with this docking site . Conversion of these helical peptide inhibitors into affinity labeling reagents led to the localization of the substrate docking site to the presenilin NTF/CTF interface (Kornilova et al., 2005) . Transition-state analog inhibitors also bind directly to the NTF/CTF interface but at a site distinct from that of helical peptide inhibitors. These findings suggest a pathway for g-secretase substrate from the docking site to the active site: upon binding to the outer surface of presenilin at the NTF/CTF interface, the substrate can pass between these two presenilin subunits to access the internal active site.
g-Secretase has in many ways been an attractive target for Alzheimer therapeutics (Wolfe, 2008) , with one inhibitor (compound 3, Figure 2 ) now in advanced clinical trials (Siemers et al., 2007) . However, interference with Notch processing and signaling might lead to toxicities that preclude clinical use of such inhibitors. Long-term treatment with gsecretase inhibitors causes severe gastrointestinal toxicity and interferes with the maturation of B-and T-lymphocytes in mice, effects that are indeed owing to inhibition of Notch processing and signaling (Searfoss et al., 2003; Wong et al., 2004) . However, compounds that can modulate the enzyme to alter or block Ab production with little or no effect on Notch would bypass this potential roadblock to therapeutics. Such compounds have indeed been identified that can alter substrate selectivity and the sites of substrate proteolysis, both in cells and in purified biochemical systems.
Certain non-steroidal anti-inflammatory drugs (NSAIDs) can reduce the production of the highly aggregation-prone Ab42 peptide and increase a 38-residue form of Ab (Weggen et al., 2001) . The alteration of the proteolytic cleavage site is observed with isolated or purified g-secretase Weggen et al., 2003; Fraering et al., 2004) , indicating that the compounds can interact directly with the protease complex to exert these effects. The site of cleavage within the Notch transmembrane domain could be similarly affected, but this subtle change does not inhibit the release of the intracellular domain and thus does not affect Notch signaling (Okochi et al., 2006) . One compound, (R)-flurbiprofen (tarenflurbil; Flurizan; compound 4 in Figure 2 ) entered late-stage clinical trials but failed owing to lack of efficacy (Green et al., 2009 ). The exact target and mechanism of action of these NSAIDs in altering g-secretase cleavage of APP remains unsettled Beher et al., 2004; Sato et al., 2006b) . A recent study suggests that the substrate itself is the target, specifically in the region of APP substrate at the extracellular/membrane junction (Kukar et al., 2008) .
Other allosteric modulators resemble kinase inhibitors and interact with a nucleotide binding site on the g-secretase complex. The discovery that ATP can increase Ab production in membrane preparations prompted the testing of a variety of compounds that interact with ATP binding sites on other proteins (Netzer et al., 2003) . In this focused screen, the Abl kinase inhibitor Gleevec emerged as a selective inhibitor of Ab production in cells without affecting the proteolysis of Notch. In light of these findings, ATP and other nucleotides were tested for effects on purified g-secretase preparations and found to selectively increase the proteolytic processing of a purified recombinant APP-based substrate without affecting the proteolysis of a Notch counterpart (Fraering et al., 2005) . Furthermore, certain compounds known to interact with ATP binding sites (e.g., compound 5 in Figure 2 ) were found to selectively inhibit APP processing vis-à-vis Notch in purified protease preparations. These and other results suggest that the g-secretase complex contains a nucleotide binding site and that this site allows allosteric regulation of g-secretase processing of APP with respect to Notch. Whether this regulation is physiologically important is unclear, but the pharmacological relevance is profound and might lead to new therapeutic candidates for Alzheimer's disease.
Toward the structure of g-secretase
The purification of the g-secretase complex (Fraering et al., 2004) allowed the first glimpse into its structure. Electron microscopy (EM) with negative heavy-atom staining and single-particle analysis reveals that the complex has a globular structure that at low resolution (10-15 Å ) appears rather amorphous (Lazarov et al., 2006) . Nevertheless, two important features were gleaned. The first is a rather large lowdensity interior cavity of approximately 20 Å diameter that is presumably where the active site resides. The second is the presence of two small openings that might be the site of entry for water.
Recently, an improved structure of g-secretase was determined by cryo-EM at 12 Å resolution (Osenkowski et al., 2009; see Figure 3 ). Cryo-EM reveals a protein structure itself, rather than a surface of the protein structure coated by a heavy metal stain. The new cryo-EM structure reveals three smaller low-density interior regions, regions that do not coalesce to form a single chamber as observed in the negative stain structure (Lazarov et al., 2006) . The cryo-EM structure has better definition than the previous negative-stained structure in that the approximately 4-nm-thick transmembrane region and four extracellular density domains are resolved (Osenkowski et al., 2009) . The structure reveals an apparent groove that could be the initial substrate docking site.
Other structural features have been revealed by cysteine mutagenesis with cross-linking of chemical probes (Sato et al., 2006a; Tolia et al., 2006) . A cysteine-less version of presenilin retained the ability to assemble with other complex members, undergo endoproteolysis to NTF and CTF, and process APP, and this allowed incorporation of single cysteine resides at various sites near the key aspartates. Disulfide formation with thiol-containing reagents then provided Signal peptides are removed from membrane proteins by signal peptidase, and the remnant peptides are released from the membrane by SPP-mediated intramembrane proteolysis. SPP, like presenilin, contains two aspartates essential for protease activity, but the conserved aspartate-containing motifs are in the opposite orientation compared with their presenilin counterparts. Consistent with the flipped orientation of SPP vis-à-vis presenilin, the substrates of these two proteases also run in the opposite direction. Unlike presenilin, SPP apparently does not require other protein cofactors or cleavage into two subunits for proteolytic activity.
information about the relative accessibility of these sites from the aqueous milieu, allowing the construction of a model in which water can funnel down to where the aspartates reside. Furthermore, simultaneous mutation of the two conserved transmembrane aspartates to cysteine and apparent intramolecular crosslinking provided the first evidence that these two aspartates are indeed in close proximity (Tolia et al., 2006) . which is required for them to coordinate and serve catalytic function. Using this same approach (cysteine mutagenesis and crosslinking), two more recent studies suggest that TMD 9 serves as a gatekeeper for lateral entry of the substrate TMD (Sato et al., 2008; Tolia et al., 2008) . Still another cysteine-crosslinking study suggested that TMD1 is in direct contact with TMD8 (Kornilova et al., 2006) . More detailed information will probably require a crystal structure of presenilin or a presenilin homolog.
SPP and SPP-like proteases
The concept of presenilin as the catalytic component for g-secretase was considerably strengthened when SPP was found to be a similar intramembrane aspartyl protease (Figure 4) . SPP clears remnant signal peptides from the membrane after their production by signal peptidase. However, this process apparently also plays a role in immune surveillance, in which signal peptides from the major histocompatibility complex (MHC) type I are cleaved by SPP. The resultant peptide products are then presented on the cell surface as an indication to natural killer cells whether MHC synthesis is proceeding normally (Lemberg et al., 2001 ). In addition, SPP is exploited by the hepatitis C virus for the maturation of its core protein, suggesting that this protease could be a suitable target for antiviral therapy (McLauchlan et al., 2002) .
SPP was identified by affinity labeling with a peptidomimetic inhibitor, and the protein sequence displayed similarities with presenilin (Weihofen et al., 2002) . SPP contains two conserved aspartates, each predicted to lie in the middle of a transmembrane domain, and the aspartate-containing sequences resemble those found in presenilins. The predicted topology of SPP also resembles that of presenilins, placing the key aspartates in the same relative position to each other in the membrane. However, the orientation of the aspartatecontaining transmembrane domains of SPP is apparently opposite that of presenilins, in correlation with the orientation of SPP substrates, which is opposite that of g-secretase substrates. Interestingly, before the identification of SPP, a computational search for presenilin-like proteins netted an entire family of so-called presenilin homologs (PSHs) (Ponting et al., 2002) ; however, it is not yet clear if all of these proteins have catalytic activity. Two homologs, SPP-like proteases, SPPL2a and SPPL2b, apparently cleave tumor necrosis factor a (Fluhrer et al., 2006) and the dementia-associated Bri2 protein (Martin et al., 2008) , although the biological roles of these proteolytic events are unknown. SPP has also been identified in malarial parasites and could represent a worthwhile therapeutic target (Nyborg et al., 2006) . SPP appears to be less complicated than g-secretase. Expression of human SPP in yeast reconstituted the protease activity, suggesting that the protein has activity on its own and does not require other mammalian protein cofactors (Weihofen et al., 2002) This has been confirmed by the expression of various SPP orthologs in E. coli and purification of active enzyme to homogeneity . Moreover, unlike presenilins, SPP is not processed into two pieces. Thus, SPP might be a more tractable enzyme for understanding intramembrane aspartyl proteases and could shed light on g-secretase structure and function. Indeed, the catalytic sites of the two proteases appear remarkably similar: their activities are inhibited by some of the same active site-directed peptidomimetics (Kornilova et al., 2003; Weihofen et al., 2003) and helical peptides (Sato et al., 2006b) , and activity can be modulated by the same NSAIDs that affect g-secretase (Sato et al., 2006b ). The ability to express SPP as a single protein in bacteria and purify it in active form suggests that this presenilin-like protease could be amenable to crystallization and high-resolution structure determination, as has been accomplished for the serine protease rhomboid (Wang et al., 2006; Wu et al., 2006; Ben-Shem et al., 2007; Lemieux et al., 2007; Wang and Ha, 2007) and the metalloprotease S2P (Feng et al., 2007) .
Conclusions
Aspartyl I-CLiPs are found in all forms of life and play essential roles in biology and disease. How these enzymes carry out hydrolysis in the membrane is a fascinating question that is not entirely resolved, but evidence suggests an initial substrate docking site and a lateral gate into a pore where water and the active site aspartates reside. Designed inhibitors have been crucial in elucidating these mechanisms, but inhibitors targeting g-secretase for the treatment of Alzheimer's disease must avoid interfering with Notch signaling. Such compounds have been identified and represent a promising class of drug candidates. Aspartyl I-CLiPs have so far eluded atomic-resolution structure determination, but EM and mutagenesis studies have offered information about the general shape and contours of the g-secretase complex. SPP could represent a convenient model system that will more easily allow crystallization and detailed structure elucidation. However, the biochemistry and biology of the SPP family are worthy of study in their own right, and these presenilinlike proteases might prove to be worthwhile therapeutic targets as well.
